The MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model is one of the most widely used and well-characterized toxin-based models of Parkinson's disease (PD)[1]. MPTP is a neurotoxin that selectively destroys dopaminergic neurons in the substantia nigra pars compacta (SNc), producing a parkinsonian phenotype in mice.
MPTP was first identified as a cause of parkinsonism in 1982 when a batch of synthetic heroin contaminated with MPTP produced severe PD-like symptoms in drug users. This accidental discovery led to the development of the MPTP mouse model, which remains a cornerstone of PD research[2].
| Variant | Protocol | Key Features |
|---|---|---|
| Acute | 4 injections, 2h apart | Rapid onset, transient effects |
| Chronic | Daily injections, 5-28 days | Progressive degeneration |
| Subacute | 5 daily injections | Most commonly used |
| MPTP + probenecid | MPTP + probenecid | Enhanced toxicity |
| Advantage | Description |
|---|---|
| High reproducibility | Consistent lesion across mice |
| Rapid onset | Symptoms within days |
| Well-characterized | Extensive literature available |
| Clinical relevance | Similar to toxin-induced PD |
| Low cost | Inexpensive to maintain |
| Limitation | Description |
|---|---|
| Acute model | Doesn't capture chronic progression |
| No Lewy bodies | Lacks hallmark protein inclusions |
| Non-human MPTP | Not found in environment |
| Reversibility | Some recovery possible |
The MPTP model is used to evaluate:
Used to investigate:
Przedborski S, et al. MPTP model of Parkinson disease. Nature. 2000. ↩︎
Jang H, et al. MPTP-induced Parkinsonism in mice: mechanisms and therapeutic targets. Nat Rev Neurol. 2024. ↩︎